Comparative Pharmacology
Head-to-head clinical analysis: LISINOPRIL AND HYDROCHLOROTHIAZIDE versus MONOPRIL HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LISINOPRIL AND HYDROCHLOROTHIAZIDE versus MONOPRIL HCT.
LISINOPRIL AND HYDROCHLOROTHIAZIDE vs MONOPRIL-HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lisinopril is an ACE inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing diuresis and lowering blood pressure.
Fosinopril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion; hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing electrolyte and water excretion.
Initial dose: 10 mg/12.5 mg orally once daily. Titrate based on blood pressure response; maximum 40 mg/25 mg per day.
1 tablet (10-20 mg fosinopril / 12.5-25 mg hydrochlorothiazide) orally once daily; maximum dose 80 mg fosinopril / 50 mg hydrochlorothiazide per day.
None Documented
None Documented
Lisinopril: terminal half-life 12 hours, effective half-life ~30 hours due to prolonged ACE inhibition. Hydrochlorothiazide: terminal half-life 5.6-14.8 hours (mean 9.6 hours) in patients with normal renal function.
Fosinoprilat: 11.5-12 h (terminal half-life extended in renal and hepatic impairment); hydrochlorothiazide: 5.6-14.8 h (varies with renal function).
Lisinopril: primarily renal (100% unchanged in urine). Hydrochlorothiazide: renal (≥95% unchanged via tubular secretion).
Fosinopril: renal (44%), biliary (46%); hydrochlorothiazide: renal (>95% as unchanged drug).
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor/Diuretic Antihypertensive